THE HOPE (HEART OUTCOMES PREVENTION EVALUATION) STUDY - THE DESIGN OFA LARGE, SIMPLE RANDOMIZED TRIAL OF AN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR (RAMIPRIL) AND VITAMIN-E IN PATIENTS AT HIGH-RISK OF CARDIOVASCULAR EVENTS

Authors
MINDLEN F NORDABY R RUIZ M ZAVALA A GUZMAN L MARTINEZ F DIAZ RR MACKEY C MARINO M ROMERO G ZAPATA G CUNEO C KAWAMURA T COELHO O MASSAYOCHI O BRAGA J LABRUNIE A BODANESE L MANENTI E VITOLA D NICOLAU J AMODEO C ARMAGANIJAN D BERTOLAMI M CARAMELI B CARVALHO A CIRENZA C FICHINO M FRANKEN R GHORAYEB N KADRI T LEAO P MALHEIROS F PAVANELLO R RAMIRES F RAMIRES J SAVIOLI F SOUSA A TANAJURA L TOPPS D KORNER L MARTINEZ V BAPTIE B BASINGER M BAYLIS B BERESFORD P EDWARDS A GIANNACCARO P GROENEWOUD Y GROSE M KELLEN J LAM S LESOWAY R MA P MELDRUM D MITCHELL D MITCHELL LB ROTH D SHUMAK S SIMON M STONE J WARNICA W WYSE D NEFFGEN C NEFFGEN J ARMSTRONG F ARMSTRONG W BELL N BLACK W BRASS N BRENNEIS F BROWNOFF R CHAYTORS G DEBANNE D DERKSEN C DONOFF M DZAVIK V GOERES M GREENWOOD P GULAMHUSEIN S HUI W HUTCHISON K KASIAN L KASZA L KRIKKE E KVILL L LAKHANI Z LINKLATER D MACKEL J MARTIN S MONTAGUE T MOORES D MUSSEAU A MUZYKA T PARADIS J PROSSER A RYAN E SENARATNE M STENERSON P TALIBI T TEO K YOUNG C ZUK V WHITE R BROWNE K BROWNE M HAPPEL K IRVING A PLESKO A DONNELLY R RADOMSKY N FELKER P LARSEN D MORSE J ROWNTREE C THOMPSON J WEDEL R BLOOMBERG G CHOMIN G DAHL M LEONG W MOY V HEATH J MARSHALL J TERWIEL M KENEFICK G KURITZKY R STEVENS K WEDDINGS K BARBAN K IMRIE J WOO K ASHTON T CALVERT K BISHOP W SWEENEY R BREAKWELL L KORNDER J PEARCE S POLASEK P RICHARDSON P GHOSH S RIELLY M WAGNER K BEMSTEIN V DAWSON K LEE P LEWIS J MACDONALD K MCGEE L THOMPSON C HILTON D ILLOTT K KLINKE P MCCONNELL J MCGEE L RABKIN S ONG A ONG G BEDARD D HOESCHEN R MEHTA P MOHAMMAD I MORRIS A BESSOUDO R DOBBINS N MCLELLAN L MILTON J DAVIS R OKEEFE D SMITH R JOYCE C PARSONS M SKANES J SUSSEX B TOBINI M RAVALIA M SHERMAN G WORRALL G ATKINSON A HATHEWAY R JOHNSON B BARNHILL S BATA I COSSEET J JOHNSTONE D MACFARLANE M SHERIDAN W CROSSMAN L FOLKINS D SHIRLEY M MACHEL T MORASH J GUPTA M MAYICH M VAKANI T BAITZ T MACPHEE E TURTON E TURTON M CHAN N MISTERSKI J RACO D CURNEW G FALLEN E FINKELSTEIN L GERSTEIN H HARDMAN P LAWAND S LONN E MAGI W MCQUEEN M PANJU A PATTERSON R SULLIVAN B SULLIVAN H SULLIVAN M TAYLOR K WORRON I YUSUF S CAMERON W NOSEWORTHY C HOULDEN R LAVALLE T FOWLIS R JANZEN I ARNOLD M CANN M CARROLL S DUMARESQ S EDMONDS M FURLONG P GEDDES C GRAHAM E HARRIS K HRAMIAK I KENNEDY R KOSTUK W KRUPA M LENT B LOVELL M MACLEAN C MASSEL D MCMANUS R MCSHERRY J MUNOZ C OCCHIPINTI J OOSTERVELD L PFLUGFELDER P POWERS S SOUTHERN R SPENCE D SQUIRES P WETMORE S WILLING J WISENBERG G WOLFE B KANNAMPUZHA P REBANE T SLUZAR V HESS A CHAN Y THOMSON D BAIGRIE R DUBBIN J LIUNI C TAN KW BRANKSTON E HEWSON P HRYCYSHYN B KAPUSTA W KNOX L LOCKNER C WHITSITT P BAIRD M CONROY D DAVIES RA DAVIES RF FRASER M HAGAR S HIERLIHY P KEELY E KHAN S LAU DGW MAROIS L NEMETH K REEVES E TUREK M VEXLER R YOUNG D KUMAR G KURUVILLA G KURUVILLA P LOWE D KWOK K BLAKELY J STYLING S BOZEK B CHARLES J FELL D FELL DA GOODE E GROSSMAN LD MATTHEWS E NITKIN R RICCI J SELBY A SINGH N SWAN J EMMETT J WEINGERT M BAIGRIE R GANJAVI F HILL D NAWAZ S HESSIAN R KWIATKOWSKI K LAI C MULAISHO C OKEEFE H SMITH H WEEKS A ANDREWS J BARNIE A DROBAC M HACKER P HANNA A IWANOCHKO M KENSHOLE A LANGER A LIU P MACLEAN S MOE G SASSON Z STERNBERG L TRACHUK C WALTERS J ZINMAN B CHEUNG M CINA C YAO L MAN K FULOP J GLANZ A SIBBICK M CARTER P OOSTERVELD L HICKEY J MCMILLIAN E DION D STHILAIRE R COUTU D DAMOURS G STARRA R BROOKS J DECHAMPS P KIWAN G KOUZ S LAFOREST M REMILLARD C BELLAMY D BROSSOIT R CARRIER S HOUDE A LABONTE I BELANGER A KANDALAFT N QUENNEVILLE L SANDI M AUGER P BILODEAU N DELAGE F DUMONT F GIROUX R LOISEL R POIRIER C SAULNIER D CARMICHAEL P LEMAY C LENIS J ARISJILWAN N BEDARD H CASAVANT C CHIASSON J DAGENAIS D FITCHETT D GOSSARD D HALLE H HAMEL N JOYAL M MAGNAN O METHE M PEDNEAULT L PILON C POISSON D PRIMEAU L RONDEAU C ROY C RUEL M SERPA A SESTIER F SMILOVITCH M THEROUX P BEAUDOIN J BOUDREAULT JR DAMOURS D DOUVILLE T GIGUERE G HOUDE G LABBE R LACHANCE S LESSARD L MERCIER G NOEL HP TALBOT P TREMBLAY J KARABATSOS A MACLELLAN K WILSON P BOGATY P LAFORGE D LANGLAIS M LEBLANC M SAMSON M TURCOTTE J CAMPEAU J DUPUIS R LAUZON C OUIMET F PRUNEAU G DESMARIS C FRECHETTO I GERVAIS P BROPHY J LEROUX S BESTER S MEUNIER L SAYEED M HART M MOUMNE I THOMASSE G WALKER J WALKER M AHMED S HABIB NM HABIB NM KUNY P LOPEZ J KLEIN W GRISOLD M HEYNDRICKX L FIASSE A DEGAUTE JP MOCKEL J DUPREZ D CHAUDRON JM BODSON A KRZENTOWSKI G BOLAND J KOLENDORF K WINTHER B JUHL H HAMALAINEN T SIITONEN O GIN H RIGALLEAU V HENSEN J RIEL R OEHMENBRITSCH R SCHULZESCHLEPPINGHOFF B HOPF R MOLLER A ROSAK C WETZEL H HASSLACHER C MARTIN T STEIN J ERDMANN E BOHM M HARTMANN D BREIDERT M FRITZEN R SCHERBAUM W MANN J MAUS J SCHROEDER C HENRICHS H UNGER H ICKENSTEIN G KROMER E RIEGGER G SCHUNKERT H BASAN B HAMPEL R CREAN P GARADAH T WHITE U MARINI N PACIARONI E SACCOMANO G
Citation
F. Mindlen et al., THE HOPE (HEART OUTCOMES PREVENTION EVALUATION) STUDY - THE DESIGN OFA LARGE, SIMPLE RANDOMIZED TRIAL OF AN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR (RAMIPRIL) AND VITAMIN-E IN PATIENTS AT HIGH-RISK OF CARDIOVASCULAR EVENTS, Canadian journal of cardiology, 12(2), 1996, pp. 127-137
Citations number
41
Categorie Soggetti
Cardiac & Cardiovascular System
Journal title
Canadian journal of cardiology → ACNP
ISSN journal
0828282X
Volume
12
Issue
2
Year of publication
1996
Pages
127 - 137
Database
ISI
SICI code
0828-282X(1996)12:2<127:TH(OPE>2.0.ZU;2-1
Abstract
OBJECTIVE: To describe the design of the HOPE (Heart Outcomes Preventi on Evaluation) Study. DESIGN: Description of the key design features o f HOPE, a large, simple randomized trial of two widely applicable trea tments - ramipril, an angiotensin-converting enzyme inhibitor; and vit amin E, a naturally occurring antioxidant vitamin - in the prevention of myocardial infarction, stroke or cardiovascular death. SETTING: Two -hundred and sixty-seven hospitals, physician offices and clinics in C anada, the United States, Mexico, Europe and South America. PATIENTS: Over 9000 women and men aged 55 years and above at high risk for cardi ovascular events such as myocardial infarction and stroke were recruit ed over 18 months. INTERVENTIONS: A 2x2 factorial design with ramipril and vitamin E with follow-up for up to four years. CONCLUSIONS: HOPE will be one of the largest trials of two new interventions to prevent myocardial infarction, stroke or cardiovascular death in high risk pat ients. The results of HOPE will have direct public health impact and a re likely to be readily incorporated into clinical practice. Key desig n features of HOPE are inclusion of individuals at high risk of cardio vascular disease, inclusion of a substantial proportion of patients wi th diabetes (36%) and women (27%), and detailed substudies to provide data on mechanisms of benefit.